Enorama Pharma AB (ERMA) - Net Assets
Based on the latest financial reports, Enorama Pharma AB (ERMA) has net assets worth Skr-23.45 Million SEK (≈ $-2.52 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr8.26 Million ≈ $889.12K USD) and total liabilities (Skr31.71 Million ≈ $3.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read ERMA total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-23.45 Million |
| % of Total Assets | -283.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | -209.82% |
| 10-Year Change | -358.28% |
| Growth Volatility | 352.96 |
Enorama Pharma AB - Net Assets Trend (2014–2025)
This chart illustrates how Enorama Pharma AB's net assets have evolved over time, based on quarterly financial data. Also explore ERMA total asset value for the complete picture of this company's asset base.
Annual Net Assets for Enorama Pharma AB (2014–2025)
The table below shows the annual net assets of Enorama Pharma AB from 2014 to 2025. For live valuation and market cap data, see Enorama Pharma AB market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr-23.45 Million ≈ $-2.52 Million |
-400.54% |
| 2024-12-31 | Skr7.80 Million ≈ $839.73K |
-60.06% |
| 2023-12-31 | Skr19.54 Million ≈ $2.10 Million |
-38.02% |
| 2022-12-31 | Skr31.52 Million ≈ $3.39 Million |
+47.63% |
| 2021-12-31 | Skr21.35 Million ≈ $2.30 Million |
+1101.69% |
| 2020-12-31 | Skr1.78 Million ≈ $191.23K |
-75.25% |
| 2019-12-31 | Skr7.18 Million ≈ $772.64K |
-57.81% |
| 2018-12-31 | Skr17.02 Million ≈ $1.83 Million |
+131.20% |
| 2017-12-31 | Skr7.36 Million ≈ $792.18K |
-18.93% |
| 2016-12-31 | Skr9.08 Million ≈ $977.10K |
+39.17% |
| 2015-12-31 | Skr6.52 Million ≈ $702.09K |
+145.26% |
| 2014-12-31 | Skr2.66 Million ≈ $286.26K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Enorama Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.65 Million | % |
| Total Equity | Skr-23.45 Million | 100.00% |
Enorama Pharma AB Competitors by Market Cap
The table below lists competitors of Enorama Pharma AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Income & Growth VCT
LSE:IGV
|
$2.25 Million |
|
Amedeo Air Four Plus Limited
LSE:AA4
|
$2.25 Million |
|
BATHURST METALS CORP.
F:J1Q0
|
$2.25 Million |
|
GREEN SHIFT COMMODITIES
F:7WV
|
$2.25 Million |
|
Gibui Holdings Ltd
TA:GIBUI
|
$2.25 Million |
|
Vp plc
LSE:VP
|
$2.24 Million |
|
CLARITY METALS CORP.
F:27G0
|
$2.24 Million |
|
Dragon Mountain Gold Ltd
AU:DMG
|
$2.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Enorama Pharma AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,803,000 to -23,451,000, a change of -31,254,000 (-400.5%).
- Net loss of 75,139,000 reduced equity.
- New share issuances of 31,174,000 increased equity.
- Other factors increased equity by 12,711,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-75.14 Million | -320.41% |
| Share Issuances | Skr31.17 Million | +132.93% |
| Other Changes | Skr12.71 Million | +54.2% |
| Total Change | Skr- | -400.54% |
Book Value vs Market Value Analysis
This analysis compares Enorama Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr0.57 | Skr0.28 | x |
| 2015-12-31 | Skr1.41 | Skr0.28 | x |
| 2016-12-31 | Skr2.16 | Skr0.28 | x |
| 2017-12-31 | Skr1.53 | Skr0.28 | x |
| 2018-12-31 | Skr3.21 | Skr0.28 | x |
| 2019-12-31 | Skr1.07 | Skr0.28 | x |
| 2020-12-31 | Skr0.26 | Skr0.28 | x |
| 2021-12-31 | Skr2.84 | Skr0.28 | x |
| 2022-12-31 | Skr3.32 | Skr0.28 | x |
| 2023-12-31 | Skr0.71 | Skr0.28 | x |
| 2024-12-31 | Skr0.15 | Skr0.28 | x |
| 2025-12-31 | Skr-0.34 | Skr0.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Enorama Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2743.30%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-254.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -0.75% | -1.45% | 0.37x | 1.39x | Skr-286.00K |
| 2015 | -10.06% | -32.90% | 0.22x | 1.41x | Skr-1.31 Million |
| 2016 | -86.31% | -196.33% | 0.29x | 1.50x | Skr-8.74 Million |
| 2017 | -118.94% | -556.67% | 0.10x | 2.10x | Skr-9.49 Million |
| 2018 | -96.01% | -310.87% | 0.14x | 2.28x | Skr-18.04 Million |
| 2019 | -344.33% | -324.83% | 0.18x | 5.93x | Skr-25.44 Million |
| 2020 | -1345.02% | -1113.75% | 0.05x | 23.02x | Skr-24.08 Million |
| 2021 | -133.67% | -258.64% | 0.22x | 2.39x | Skr-30.68 Million |
| 2022 | -132.53% | -610.19% | 0.14x | 1.55x | Skr-44.93 Million |
| 2023 | -228.34% | -3285.20% | 0.04x | 1.76x | Skr-46.57 Million |
| 2024 | -561.40% | -277.82% | 0.99x | 2.04x | Skr-44.59 Million |
| 2025 | 0.00% | -2743.30% | 0.33x | 0.00x | Skr-72.79 Million |
Industry Comparison
This section compares Enorama Pharma AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $635,861,533
- Average return on equity (ROE) among peers: -41.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Enorama Pharma AB (ERMA) | Skr-23.45 Million | -0.75% | N/A | $2.25 Million |
| BioGaia AB (publ) (BIOG-B) | $463.89 Million | 38.92% | 0.24x | $1.26 Billion |
| Enzymatica publ AB (ENZY) | $-901.48K | 0.00% | 0.00x | $66.35 Million |
| Gabather AB (publ) (GABA) | $3.44 Million | -248.55% | 0.96x | $1.04 Million |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $23.19 Million |
| Moberg Pharma AB (publ) (MOB) | $201.49 Million | -5.64% | 0.35x | $58.17 Million |
| Nanexa AB (NANEXA) | $16.96 Million | -37.43% | 0.21x | $60.08 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $49.38 Million | -39.35% | 0.48x | $4.48 Million |
| Orexo AB (ORX) | $25.52 Million | -81.53% | 0.30x | $70.45 Million |
| Swedish Orphan Biovitrum AB (publ) (SOBI) | $4.96 Billion | 0.36% | 0.35x | $15.91 Billion |
About Enorama Pharma AB
Enorama Pharma AB (publ), a pharmaceutical company, develops, manufactures, and sells medicated chewing gum in Sweden. It offers nicotine chewing gum and nicotine pouches under the NIC-S brand name. The company was incorporated in 2006 and is based in Malmö, Sweden.